A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

263

Participants

Timeline

Start Date

April 21, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Healthy Volunteer

Interventions

DRUG

Risankizumab

Subcutaneous Injection

Trial Locations (4)

Cpmi /Id# 274464, Miami

Acpru /Id# 271954, Grayslake

Collaborative Neuroscience Research CNS /ID# 275212, Los Alamitos

CenExel ACT- Anaheim Clinical Trials /ID# 274805, Anaheim